$6,165 Mln
$-616 Mln
--
As on 14-Mar-2022 09:30 EDT
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Arena Pharmaceuticals Inc (ARNA)
| 7.59 | 6.59 | 11.00 | 29.74 | 29.86 | 47.34 | 18.57 |
|
S&P BSE Sensex*
| 8.49 | 1.22 | 3.91 | 11.02 | 20.17 | 12.37 | 12.54 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|
|---|---|---|---|---|---|---|---|
|
Arena Pharmaceuticals Inc (ARNA)
| 20.97 | 69.15 | 16.61 | 14.57 | 139.23 | -25.26 | -45.24 |
|
S&P BSE Sensex
| 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 | -5.03 |
|
S&P BSE Sensex
| 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 | -5.03 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Arena Pharmaceuticals Inc (ARNA) stood at $ 785 Mln as on 31-Dec-21
The share price of Arena Pharmaceuticals Inc (ARNA) is $99.990000 (NASDAQ) as of 14-Mar-2022 09:30 EDT. Arena Pharmaceuticals Inc (ARNA) has given a return of 29.86% in the last 3 years.
Arena Pharmaceuticals Inc (ARNA) has a market capitalisation of $ 6,165 Mln as on 14-Mar-2022. As per Value Research classification, it is a company.
The P/B ratio of Arena Pharmaceuticals Inc (ARNA) is 9.16 times as on 14-Mar-2022, a 2.61% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Arena Pharmaceuticals Inc (ARNA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Arena Pharmaceuticals Inc (ARNA) and enter the required number of quantities and click on buy to purchase the shares of Arena Pharmaceuticals Inc (ARNA).
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
The CEO & director of Mr. Amit D. Munshi M.B.A.. is Arena Pharmaceuticals Inc (ARNA), and CFO & Sr. VP is Ms. Laurie D. Stelzer.
The promoters of Arena Pharmaceuticals Inc (ARNA) have pledged 0% of the total equity as on Feb-22.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
523
|
|
|
498
|
|
|
497
|
|
|
392
|
| Arena Pharmaceuticals Inc (ARNA) | Ratios |
|---|---|
|
Return on equity(%)
|
-70.3
|
|
Return on capital employed(%)
|
-66.98
|
|
Debt-to-equity ratio
|
0.06
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Arena Pharmaceuticals Inc (ARNA) was $-616 Mln.
$6,165.32 Mln
$-3.48 Mln
$-616.43 Mln
$550.47 Mln
$41.21 Mln
$-- - --
61,659,400
NASDAQ: ARNA
Park City, UT
https://www.arenapharm.com
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase... III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
